The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Wednesday broker round-up UPDATE

Wed, 22nd May 2013 09:37

Afferro Mining: Panmure Gordon reduces target price from 279p to 100p, while keeping its buy recommendation.Amara Mining: Westhouse Securities cuts target price from 110p to 90p retaining a buy recommendation.Amlin: Westhouse Securities moves target price from 455p to 470p and upgrades to add.ARM Holdings: Berenberg increases target price from 1150p to 1350p and maintains a buy recommendation.Beazley: Westhouse Securities shifts target price from 235p to 245p, while downgrading to neutral.Britvic: Investec places both its target price (prev.: 447p) and its buy recommendation under review.Burberry: JP Morgan increases target price from 1320p to 1400p and keeps a neutral rating. Deutsche Bank raises target price from 1400p to 1530p, while its hold recommendation remains unchanged. Credit Suisse ups target price from 1550p to 1600p and maintains an outperform rating.Capita Group: Investec ups target price from 865p to 1000p upgrading from sell to hold. HSBC Holdings increases target price from 775p to 1050p upgrading to neutral.Carnival: Morgan Stanley reduces target price from 2400p to 2200p, while reiterating an equal-weight rating. Deutsche Bank cuts target price from 2780p to 2640p staying with its buy recommendation. Exane takes target price from 2400p to 2200p and retains a neutral rating. HSBC Holdings reduces target price from 2900p to 2500p and downgrades to neutral.Catlin Group: Westhouse Securities takes target price from 530p to 590p upgrading to add.Darty: Citi shifts target price from 39p to 47p, but still recommends selling. Exane moves target price from 50p to 65p and maintains a neutral rating. Societe Generale takes target price from 51p to 68p, while downgrading to hold.Faroe Petroleum: Jefferies lowers target price from 210p to 200p, while keeping its buy recommendation.First Group: Morgan Stanley cuts target price from 195p to 176p, while upgrading to equal-weight.GlaxoSmithKline: Exane raises target price from 1400p to 1500p, but keeps its underperform rating.Great Portland Estates: Investec increases target price from 515p to 630p, while reiterating an add rating.Griffin Mining: Cantor Fitzgerald ups target price from 40p to 70p and upgrades to buy.Hikma Pharmaceuticals: Credit Suisse takes target price from 820p to 1050p, while its outperform rating is kept.Hiscox: Westhouse Securities shifts target price from 530p to 540p and keeps a neutral rating.Hogg Robinson Group: Investec lowers target price from 100p to 95p, while maintaining its buy recommendation. Canaccord Genuity shifts target price from 90p to 85p and retains a buy recommendation.Homeserve: Jefferies ups target price from 210p to 240p keeping a hold recommendation.HSBC Holdings: Bank of America ups target price from 755p to 785p and reiterates a neutral rating.Imagination Technologies Group: Berenberg reduces target price from 360p to 250p and leaves its sell recommendation unchanged.Informa: Westhouse Securities downgrades from add to neutral with a target price of 525p.Innovation Group: Investec moves target price from 30p to 33p maintaining a buy recommendation. Panmure Gordon shifts target price from 38p to 39p and keeps a buy recommendation.Invensys: Exane raises target price from 350p to 380p reiterating a neutral rating.Kazakhmys: UBS reduces target price from 465p to 385p and downgrades from buy to neutral.Magnolia Petroleum: Northland Capital initiates with a target price of 4.60p and a buy recommendation.Man Group: Citi moves target price from 110p to 130p and retains a neutral rating.Marks & Spencer: Nomura increases target price from 500p to 540p maintaining a buy recommendation. Citi ups target price from 440p to 470p and stays with its neutral rating. Deutsche Bank moves target price from 450p to 465p and leaves its hold recommendation unaltered. Exane raises target price from 310p to 390p keeping an underperform rating. Societe Generale ups target price from 472p to 581p and retains a buy recommendation. HSBC Holdings takes target price from 390p to 490p and maintains a neutral rating.MITIE: Jefferies cuts target price from 300p to 285p and maintains a hold recommendation.NetDimensions: Panmure Gordon ups target price from 118p to 124p reiterating its buy recommendation.Novae Group: Westhouse Securities raises target price from 450p to 500p and retains a neutral rating.Optimal Payments: Canaccord Genuity takes target price from 200p to 220p and retains a buy recommendation.Optos: N+1 Singer reduces target price from 150p to 135p, while upgrading to hold.Paragon Group: JP Morgan moves target price from 300p to 361p maintaining an overweight rating.Petropavlovsk: Westhouse Securities lowers target price from 285p to 275p keeping its buy recommendation.PZ Cussons: Panmure Gordon increases target price from 380p to 400p and retains a hold recommendation.RPS Group: Jefferies lowers target price from 285p to 275p, while leaving its buy recommendation unchanged.Shaftesbury: Investec takes target price from 550p to 690p and retains a hold recommendation.UK Mail Group: Investec raises target price from 465p to 600p and stays with its buy recommendation.Vectura: JP Morgan shifts target price from 133p to 148p and stays with its overweight rating.
More News
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.